These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28413972)

  • 1. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
    Schuchardt M; Herrmann J; Tolle M; van der Giet M
    Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid lowering therapy in cardiovascular diseases.
    Volterrani M; Iellamo F; Sposato B; Romeo F
    Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
    Gavin AR; Struthers AD
    Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
    Berry CE; Hare JM
    J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel xanthine oxidoreductase inhibitor for hyperuricemia treatment with high efficacy and safety profile.
    Li X; Chen D; Qi C; Yang Y; Guo K; Ma C; Tian J; Li J; Zhang L; Wang B; Xiao Z; Ye F
    Biomed Pharmacother; 2024 Sep; 178():117223. PubMed ID: 39094541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia and cardiovascular disease risk.
    Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
    Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
    Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase.
    Sekine M; Okamoto K; Ichida K
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.
    Higgins P; Dawson J; Lees KR; McArthur K; Quinn TJ; Walters MR
    Cardiovasc Ther; 2012 Aug; 30(4):217-26. PubMed ID: 22099531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing effect of mangiferin on serum uric acid levels in mice.
    Niu Y; Lu W; Gao L; Lin H; Liu X; Li L
    Pharm Biol; 2012 Sep; 50(9):1177-82. PubMed ID: 22881143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
    Niu Y; Liu J; Liu HY; Gao LH; Feng GH; Liu X; Li L
    Pharm Biol; 2016 Sep; 54(9):1680-6. PubMed ID: 26916555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
    Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
    J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
    Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
    Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
    Furuhashi M
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.